Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

The Most-Read Articles From Evidence-Based OncologyTM for 2018
December 27th 2018

The Most-Read Articles From Evidence-Based OncologyTM for 2018

Mary Caffrey
From chimeric antigen receptor T-cell therapy to value-based contracting, reimbursement issues dominated reader interest.
Reimbursement With Treatment for Multiple Myeloma
December 27th 2018

Reimbursement With Treatment for Multiple Myeloma

Studies Presented at ASH 2018 and the Outlook for Myeloma
December 27th 2018

Studies Presented at ASH 2018 and the Outlook for Myeloma

MRD Testing and Relapsed/Refractory Multiple Myeloma Treatment Options
December 27th 2018

MRD Testing and Relapsed/Refractory Multiple Myeloma Treatment Options

Transplant Patients' Options, CoMMpass Study, and Doublet Versus Triplet Therapy
December 27th 2018

Transplant Patients' Options, CoMMpass Study, and Doublet Versus Triplet Therapy

Dr Robert Daly Discusses How Clinical Pathways Can Reduce Disparities in Breast Cancer
December 25th 2018

Dr Robert Daly Discusses How Clinical Pathways Can Reduce Disparities in Breast Cancer

There can be great disparities across the country and across races when it comes to cancer care, but clinical pathways can help standardize care so everyone gets the most efficacious treatments, said Robert Daly, MD, MBA, medical oncologist, Memorial Sloan Kettering Cancer Center.
Challenges and Opportunities in the Oncology Care Model
December 23rd 2018

Challenges and Opportunities in the Oncology Care Model

Laura Joszt, MA
The practices that have been participating in CMS’ Oncology Care Model have undergone significant practice transformation in order to be successful in the program. However, even after being in the model for 2 years, there are still remaining opportunities for investment.
Diabetes, Cancer Interviews Among Most-Watched Videos of 2018
December 20th 2018

Diabetes, Cancer Interviews Among Most-Watched Videos of 2018

Laura Joszt, MA
Throughout the year, The American Journal of Managed Care® (AJMC®) offered a number of video programs, including Peer Exchange discussions and interviews, on a range of topics. Here are the most-watched videos published by AJMC® in 2018.
Dr Barbara McAneny Explains the Current Focus of Care Management in Oncology
December 20th 2018

Dr Barbara McAneny Explains the Current Focus of Care Management in Oncology

Keeping people with cancer out of the hospital is a low-hanging fruit that is of huge benefit to patients, explained Barbara L. McAneny, MD, president of the American Medical Association.
Dr Michael Kolodziej Reflects on OCM and What Might Come After
December 19th 2018

Dr Michael Kolodziej Reflects on OCM and What Might Come After

The Oncology Care Model (OCM) is not a sustainable model, but while it finishes out the 5-year pilot, CMS will likely be fine-tuning bundled payments in medical oncology, said Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc.
Report Assesses Degree of Alignment Between ASCO, ESMO Oncology Frameworks
December 18th 2018

Report Assesses Degree of Alignment Between ASCO, ESMO Oncology Frameworks

Allison Inserro
A joint assessment comparing the results of value frameworks created by the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) found that the frameworks produce comparable measures of the clinical benefits of new cancer therapies in roughly two-thirds of more than 100 drug comparisons examined.
Dr Sibel Blau Discusses Physician, Staff Education Around OCM
December 17th 2018

Dr Sibel Blau Discusses Physician, Staff Education Around OCM

Implementing the Oncology Care Model required educating physicians and staff on a new way to do the work and why the changes were necessary under the new model, explained Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Common Factors Among Successful Practices in the OCM
December 16th 2018

Common Factors Among Successful Practices in the OCM

Laura Joszt, MA
Practices participating in the Oncology Care Model have now received performance results for 2 periods, and many practices were surprised that they didn’t perform as well as expected. In general, some of the practices have found it difficult to predict success in the model, but there have been positive results from the OCM.
Dr Robert Daly Explains the Importance of Updating Pathways With New Data
December 16th 2018

Dr Robert Daly Explains the Importance of Updating Pathways With New Data

As new breakthrough therapies are approved, clinical pathways have to be kept updated in order for patients to get the best treatments, said Robert Daly, MD, MBA, medical oncologist, Memorial Sloan Kettering Cancer Center.
Podcast: This Week in Managed Care—US Uninsured Rate Increases and Other Health News
December 16th 2018

Podcast: This Week in Managed Care—US Uninsured Rate Increases and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Beth Wittmer Discusses Diet Restrictions With Neutropenia
December 15th 2018

Beth Wittmer Discusses Diet Restrictions With Neutropenia

Patients with neutropenia or at risk of it need to be cautious of their diet, said Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.
Using Cost Variation to Identify Savings Opportunities Under the OCM
December 14th 2018

Using Cost Variation to Identify Savings Opportunities Under the OCM

A study published in this month's issue of The American Journal of Managed Care® estimated standardized episode-level spending for patients across subcategories of care for each hospital referral region—defined by the Dartmouth Atlas—in order to identify the greatest opportunities for cost savings under the Oncology Care Model (OCM).
This Week in Managed Care: December 14, 2018
December 14th 2018

This Week in Managed Care: December 14, 2018

This week, the top managed care news included a report that found uninsured rates were on the rise in 2017; an analysis of rising health insurance costs for families; predictions for cardiology trends in 2019.
Equity in Cancer Care: A Viewpoint From Patient Advocates
December 13th 2018

Equity in Cancer Care: A Viewpoint From Patient Advocates

Jaime Rosenberg
A panel of patient advocates at the National Comprehensive Cancer Network Patient Advocacy Meeting, held in Washington, DC, discussed the reasons behind and consequences of inequities in cancer care.
Adherence With CDK4/6 Inhibitors
December 13th 2018

Adherence With CDK4/6 Inhibitors

Patient Management of CDK4/6 Inhibitors
December 13th 2018

Patient Management of CDK4/6 Inhibitors

Dispensing of CDK4/6 Inhibitors
December 13th 2018

Dispensing of CDK4/6 Inhibitors

Multidisciplinary Approach: Managing CDK4/6 Inhibitors
December 13th 2018

Multidisciplinary Approach: Managing CDK4/6 Inhibitors

Patients' Perspectives on CDK4/6 Inhibitors
December 13th 2018

Patients' Perspectives on CDK4/6 Inhibitors

Benefits and Challenges of CDK4/6 Inhibitors
December 13th 2018

Benefits and Challenges of CDK4/6 Inhibitors

Metastatic Breast Cancer: CDK4/6 Inhibitors
December 13th 2018

Metastatic Breast Cancer: CDK4/6 Inhibitors

Improving Care for Patients With Metastatic Breast Cancer
December 13th 2018

Improving Care for Patients With Metastatic Breast Cancer

Educating Patients and Staff on Using CDK4/6 Inhibitors
December 13th 2018

Educating Patients and Staff on Using CDK4/6 Inhibitors

Best Practices for Managing Patients on CDK4/6 Inhibitors
December 13th 2018

Best Practices for Managing Patients on CDK4/6 Inhibitors

Multidisciplinary Care in Breast Cancer
December 13th 2018

Multidisciplinary Care in Breast Cancer

<1
...
333435363738394041
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo